Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
2.

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.

Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL, Danlos FX, Dakdouki YE, Annereau M, Mariette X, Robert C, Cherif K, Marabelle A, Mateus C, Lambotte O.

Ann Rheum Dis. 2018 Jun 1. pii: annrheumdis-2018-213677. doi: 10.1136/annrheumdis-2018-213677. [Epub ahead of print] No abstract available.

PMID:
29858173
3.

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

De Martin E, Michot JM, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 May 15. pii: S0168-8278(18)32030-0. doi: 10.1016/j.jhep.2018.04.019. [Epub ahead of print] No abstract available.

PMID:
29776713
4.

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.

Eur J Cancer. 2018 Jun;96:91-104. doi: 10.1016/j.ejca.2018.03.006. Epub 2018 Apr 23.

PMID:
29698933
5.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.

PMID:
29635146
6.

Clinical Images: Remitting seronegative symmetric synovitis with pitting edema associated with partial melanoma response under anti-CTLA-4 and anti-programmed death 1 combination treatment.

Amini-Adle M, Piperno M, Tordo J, Thomas L, Dalle S, Dubois V, Marabelle A.

Arthritis Rheumatol. 2018 Mar 26. doi: 10.1002/art.40506. [Epub ahead of print] No abstract available.

PMID:
29579372
7.

Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative.

de Baère T, Tselikas L, Deschamps F, Soria JC, Marabelle A.

Cardiovasc Intervent Radiol. 2018 Jun;41(6):825-827. doi: 10.1007/s00270-018-1935-y. No abstract available.

PMID:
29549416
8.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

9.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.

PMID:
29427729
10.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
11.

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Dercle L, Ammari S, Seban RD, Schwartz LH, Houot R, Labaied N, Mokrane FZ, Lazarovici J, Danu A, Marabelle A, Ribrag V, Michot JM.

Eur J Cancer. 2018 Mar;91:136-144. doi: 10.1016/j.ejca.2017.12.015.

PMID:
29360605
12.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
13.

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O.

Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18. No abstract available.

PMID:
29269089
14.

Intratumoral immunotherapy: using the tumor as the remedy.

Marabelle A, Tselikas L, de Baere T, Houot R.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43. doi: 10.1093/annonc/mdx683. Review.

PMID:
29253115
15.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
16.

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.

Manson G, Marabelle A, Houot R.

JAMA Dermatol. 2018 Jan 1;154(1):113. doi: 10.1001/jamadermatol.2017.4421. No abstract available.

PMID:
29167871
17.

The oncolytic compound LTX-401 targets the Golgi apparatus.

Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Differ. 2018 Jan;25(1):227-228. doi: 10.1038/cdd.2017.148. Epub 2017 Nov 10.

18.

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors.

Michot JM, Pruvost R, Mateus C, Champiat S, Voisin AL, Marabelle A, Lambotte O.

Ann Oncol. 2018 Feb 1;29(2):518-520. doi: 10.1093/annonc/mdx701. No abstract available.

PMID:
29088318
19.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.

Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F.

Ann Oncol. 2017 Nov 1;28(11):2860-2865. doi: 10.1093/annonc/mdx403.

PMID:
29045560
20.

Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma.

Delloye-Bourgeois C, Bertin L, Thoinet K, Jarrosson L, Kindbeiter K, Buffet T, Tauszig-Delamasure S, Bozon M, Marabelle A, Combaret V, Bergeron C, Derrington E, Castellani V.

Cancer Cell. 2017 Oct 9;32(4):427-443.e8. doi: 10.1016/j.ccell.2017.09.006.

PMID:
29017055
21.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

22.

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

Mahjoubi L, Gazzah A, Marabelle A, Le Roy Ladurie F, Lambotte O, Caramella C, Adam J, Besse B, Soria JC.

Eur J Cancer. 2017 Nov;85:155-157. doi: 10.1016/j.ejca.2017.07.049. Epub 2017 Sep 13. No abstract available.

PMID:
28917814
23.

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S.

Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Review.

PMID:
28892775
24.

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL.

Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Review.

PMID:
28846956
25.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.

PMID:
28826074
26.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.

PMID:
28826073
27.

Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy.

Boisseau W, Touat M, Berzero G, Savatovsky J, Marabelle A, Touitou V, Ricard D, Malouf G, Psimaras D.

Eur J Cancer. 2017 Sep;83:28-31. doi: 10.1016/j.ejca.2017.05.036. Epub 2017 Jul 12. No abstract available.

PMID:
28710954
28.

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.

Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10.

PMID:
28646772
29.

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.

Ann Rheum Dis. 2017 Oct;76(10):1747-1750. doi: 10.1136/annrheumdis-2017-211216. Epub 2017 Jun 9.

PMID:
28600350
30.

18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.

Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM.

J Nucl Med. 2018 Jan;59(1):15-24. doi: 10.2967/jnumed.117.193011. Epub 2017 Jun 8.

31.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L.

Cancer Res. 2017 Aug 1;77(15):4146-4157. doi: 10.1158/0008-5472.CAN-16-2165. Epub 2017 May 23.

PMID:
28536278
32.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A.

Ann Oncol. 2017 Aug 1;28(8):1756-1766. doi: 10.1093/annonc/mdx179. Review.

PMID:
28444111
33.

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN.

Clin Cancer Res. 2017 May 15;23(10):2433-2441. doi: 10.1158/1078-0432.CCR-16-2898. Epub 2017 Apr 21.

34.

iRECIST: A clarification of tumour response assessment in the immunotherapy era.

Ferté C, Marabelle A.

Eur J Cancer. 2017 May;77:165-167. doi: 10.1016/j.ejca.2017.02.015. Epub 2017 Apr 4. No abstract available.

PMID:
28385325
35.

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.

Pradere P, Michot JM, Champiat S, Danlos FX, Marabelle A, Lambotte O, Albiges L, Le Pavec J.

Eur J Cancer. 2017 Apr;75:308-309. doi: 10.1016/j.ejca.2016.12.027. Epub 2017 Mar 1. No abstract available.

PMID:
28259013
36.

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L.

Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.

37.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

38.

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.

Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC.

Cancer Discov. 2017 Feb;7(2):128-130. doi: 10.1158/2159-8290.CD-16-1439.

39.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C.

Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.

40.

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B, Tiseo M.

J Thorac Oncol. 2016 Nov;11(11):1819-1836. doi: 10.1016/j.jtho.2016.05.027. Epub 2016 Jun 8. Review.

41.

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

de Charette M, Marabelle A, Houot R.

Eur J Cancer. 2016 Nov;68:134-147. doi: 10.1016/j.ejca.2016.09.010. Epub 2016 Oct 15. Review.

PMID:
27755997
42.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

43.

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.

44.

The oncolytic compound LTX-401 targets the Golgi apparatus.

Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Differ. 2016 Dec;23(12):2031-2041. doi: 10.1038/cdd.2016.86. Epub 2016 Sep 2. Erratum in: Cell Death Differ. 2017 Nov 10;:.

45.

Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.

Michot JM, Mazeron R, Dercle L, Ammari S, Canova C, Marabelle A, Rose S, Rubin E, Deutsch E, Soria JC, Ribrag V, Levy A.

Eur J Cancer. 2016 Oct;66:91-4. doi: 10.1016/j.ejca.2016.06.017. Epub 2016 Aug 18. No abstract available.

PMID:
27544928
46.

Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis.

Vences-Catalán F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R, Levy S.

Oncoimmunology. 2015 Dec 18;5(5):e1120399. doi: 10.1080/2162402X.2015.1120399. eCollection 2016 May.

47.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S.

Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21.

PMID:
27451022
48.

Holbrook Kohrt: In Memoriam (1977-2016).

Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A.

Clin Cancer Res. 2016 Jul 15;22(14):3695-6. doi: 10.1158/1078-0432.CCR-16-1181. No abstract available.

49.

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.

Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S.

Clin Cancer Res. 2016 Sep 1;22(17):4309-21. doi: 10.1158/1078-0432.CCR-16-0903. Epub 2016 Jul 7. Review.

50.

Can immunostimulatory agents enhance the abscopal effect of radiotherapy?

Levy A, Chargari C, Marabelle A, Perfettini JL, Magné N, Deutsch E.

Eur J Cancer. 2016 Jul;62:36-45. doi: 10.1016/j.ejca.2016.03.067. Epub 2016 May 18. Review.

PMID:
27200491

Supplemental Content

Loading ...
Support Center